RxSight (NASDAQ:RXST) Given New $11.00 Price Target at Needham & Company LLC

RxSight (NASDAQ:RXST) had its price objective trimmed by Needham & Company LLC from $13.00 to $11.00 in a research report released on Thursday morning, MarketBeat.com reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently weighed in on the stock. Piper Sandler decreased their price objective on shares of RxSight from $11.00 to $10.00 and set a “neutral” rating for the company in a research report on Thursday, February 26th. UBS Group upped their price objective on shares of RxSight from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Thursday, February 26th. Stifel Nicolaus decreased their price objective on shares of RxSight from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Monday, March 9th. William Blair began coverage on shares of RxSight in a research report on Friday, January 30th. They issued a “market perform” rating for the company. Finally, Wolfe Research upgraded shares of RxSight to an “outperform” rating in a research report on Friday, January 30th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, RxSight has an average rating of “Reduce” and a consensus price target of $9.44.

RxSight Stock Performance

Shares of RxSight stock opened at $5.80 on Thursday. The firm has a 50-day simple moving average of $7.11 and a two-hundred day simple moving average of $8.93. The company has a market cap of $240.12 million, a P/E ratio of -5.13 and a beta of 1.24. RxSight has a fifty-two week low of $5.30 and a fifty-two week high of $16.74.

Hedge Funds Weigh In On RxSight

Several hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in RxSight during the 2nd quarter worth approximately $28,000. Summit Securities Group LLC purchased a new position in shares of RxSight in the 1st quarter valued at $30,000. Larson Financial Group LLC boosted its holdings in shares of RxSight by 110.5% in the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after acquiring an additional 2,089 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of RxSight by 440.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after acquiring an additional 3,063 shares in the last quarter. Finally, CWM LLC lifted its stake in shares of RxSight by 211.1% in the fourth quarter. CWM LLC now owns 3,826 shares of the company’s stock valued at $40,000 after purchasing an additional 2,596 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.

Trending Headlines about RxSight

Here are the key news stories impacting RxSight this week:

• Positive Sentiment: Q1 revenue beat estimates — RxSight reported $30.89M in revenue vs. analyst estimates of $29.75M, a modest upside that suggests resilience in top-line demand. Zacks Q1 Revenue Beat
• Positive Sentiment: Company reiterated its full-year sales outlook in its press release, which can be read as management maintaining confidence in FY26 execution despite the quarter’s challenges. GlobeNewswire Press Release
• Neutral Sentiment: Needham cut its price target from $13 to $11 but kept a “buy” rating, signaling continued analyst conviction in upside longer term even as near-term assumptions were trimmed. Benzinga – Needham The Fly – Needham
• Negative Sentiment: Wells Fargo lowered its price target from $11 to $9 and moved to an “equal weight” rating — a clear near-term negative signal that likely pressured the stock. Benzinga – Wells Fargo
• Negative Sentiment: Q1 earnings missed estimates: RxSight reported a ($0.19) EPS vs. a ($0.12) consensus and a larger loss than a year ago, highlighting margin pressure and raising short-term profitability concerns. MarketBeat Earnings
• Negative Sentiment: FY26 revenue guidance was issued at $120M–$135M versus a consensus near $129.1M; the range includes outcomes below street expectations, which may temper near-term upside. Company Guidance
• Negative Sentiment: Brokerage consensus has shifted toward caution — the stock received an average “Reduce” rating from brokerages in a recent survey, increasing selling pressure. AmericanBankingNews

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.